Key features•Group A *Streptococcus* or *Streptococcus pyogenes* is the predominant global cause of bacterial pharyngitis and skin infection•Group A *Streptococcus* is also a cause of severe invasive, necrotizing and toxin-mediated syndromes and debilitating non-suppurative sequelae, including rheumatic fever and acute post-streptococcal glomerulonephritis•Group A *Streptococcus* is estimated to result in over 500,000 deaths annually, mostly in developing countries and mostly because of invasive infection or from rheumatic heart disease and its complications•Group A *Streptococcus* remains universally sensitive to penicillin which remains the mainstay of treatment of Group A Streptococcus infections and the prevention of rheumatic heart disease

Introduction {#s0010}
============

Group A *Streptococcus* causes a diverse spectrum of disease, ranging from benign and self-limited infection of the throat or skin, to lethal soft tissue infections accompanied by multi-organ failure. Until the advent of the antibiotic era, Group A *Streptococcus* was a major cause of death in industrialized countries as a result of sepsis, rheumatic heart disease and fatal epidemics of scarlet fever [@bib1], [@bib2]. The 1980s saw an increase in rheumatic fever cases in the Rocky Mountain states of the USA, along with an apparent resurgence in severe Group A *Streptococcus* disease in industrialized countries. The resultant increased attention paid to Group A *Streptococcus* disease in recent years has also brought to focus the continuing high burden of Group A *Streptococcus* disease in developing countries, particularly those in tropical regions [@bib3].

Epidemiology {#s0015}
============

The burden of all Group A *Streptococcus* infections is highest in resource-limited settings, most of which are in tropical regions. It is assumed that the major reasons for this relate to poverty, overcrowded living conditions and limited access to medical care, although geography and climate may also play a role. The estimated number of cases and deaths of Group A *Streptococcus* diseases is shown in [Table 36-1](#t0010){ref-type="table"} . Of the more severe diseases, 79% of rheumatic heart disease cases, 95% of acute rheumatic fever cases, 97% of acute post-streptococcal glomerulonephritis cases and 97% of invasive Group A *Streptococcus* cases come from less developed countries [@bib3].TABLE 36-1Summary of Estimated Global Burden of Group A Streptococcal DiseasesDiseaseNumber of existing casesNumber of new cases each yearNumber of deaths each yearRheumatic heart disease (RHD)15.6 million282,000[\*](#tn0010){ref-type="table-fn"}233,000[†](#tn0015){ref-type="table-fn"}History of acute rheumatic fever without carditis, requiring secondary prophylaxis1.88 million188,000[\*](#tn0010){ref-type="table-fn"}RHD-related infective endocarditis34,0008,000RHD-related stroke640,000144,000108,000Acute post-streptococcal glomerulonephritis[§](#tn0020){ref-type="table-fn"}472,0005,000Invasive group A streptococcal diseases663,000163,000**Total severe cases18.1 million1.78 million517,000**Pyoderma111 millionPharyngitis616 million[^1][^2][^3][^4]Reproduced with permission from Carapetis JR, Steer AC, Mulholland EK, Weber M. The global burden of group A streptococcal diseases. Lancet Infect Dis 2005;5:685--94.

Pharyngitis is the most common manifestation of Group A *Streptococcus* disease---its incidence is highest in school-aged children. One episode occurs every 1--2 child years in some resource-limited settings, while only 1 episode every 7--8 child years has been observed in developed urban settings. Limited data on the incidence of Group A *Streptococcus* pharyngitis in tropical areas suggest significant variability, with rates comparable to temperate climates in some settings but, in others, the documented rate is considerably lower. Transmission is higher in winter months. Impetigo is common in childhood; transmission occurs readily in school and preschool care settings, especially in the summer months. In tropical settings where the burden is particularly high, the majority of children in some communities have impetigo at any one time.

Cellulitis and erysipelas are the most frequent manifestations of invasive Group A *Streptococcus* infection and, in contrast to pharyngitis and impetigo, incidence increases with age. In the mid-1980s, reports emerged from industrialized countries of both increasing numbers of severe necrotizing Group A *Streptococcus* infections and of streptococcal toxic shock syndrome [@bib4]. Group A *Streptococcus* strains belonging to *emm* types 1 and 3, in particular, have been implicated in this rise. Most cases of severe invasive Group A *Streptococcus* disease are sporadic, but secondary cases and case clusters have been reported. Limited data suggest that both the incidence and case-fatality of invasive Group A *Streptococcus* disease in resource-limited countries is several-fold higher than in industrialized countries.

Acute rheumatic fever and rheumatic heart disease continue to result in a substantial component of Group A *Streptococcus*-related morbidity and mortality in resource-limited settings. Of the 517,000 Group A *Streptococcus*-related deaths each year, it is estimated that two thirds are caused by rheumatic heart disease or its complications [@bib3]. The true prevalence of rheumatic heart disease remains uncertain, with estimates of at least 1.3 per 1000 school-aged children in developing countries based on auscultatory screening, while estimates based on echocardiography suggest the true prevalence may be more than 10 times higher [@bib5]. Acute rheumatic fever has become uncommon in industrialized settings, although the incidence remains high among indigenous populations in Australia and New Zealand.

The incidence of acute post-streptococcal glomerulonephritis appears to be declining in industrialized settings, but sporadic cases still occur. Acute post-streptococcal glomerulonephritis continues to occur both sporadically and in epidemics in tropical climates (where Group A *Streptococcus* pyoderma is also common); limited data suggest that acute mortality and chronic morbidity from acute post-streptococcal glomerulonephritis may be higher in developing settings.

Natural History, Pathogenesis and Pathology {#s0020}
===========================================

The oropharynx and the skin of humans are the only recognized ecologic niches for Group A *Streptococcus* and they represent the major entry sites for both local and invasive infection [@bib6] (see [Fig. 36.1](#f0010){ref-type="fig"} ). Up to 20% of school-aged children may be colonized in the oropharynx in temperate and some tropical regions, although in many tropical settings, less than 5% of children carry Group A *Streptococcus* (with groups C and G streptococci being more common). Surface proteins facilitate specific adhesion of Group A *Streptococcus* to either the mucosal epithelium of the throat or to the skin (or both). Asymptomatic colonization of the oropharynx may persist at low levels for weeks without eliciting a host immune response. Colonization of the skin is more transient, becoming established only days before inoculation (e.g. by insect bite) and subsequent pyoderma.FIGURE 36.1The inter-related manifestations of Group A *Streptococcus* colonization and local and invasive infection, including immune-mediated and toxin-mediated syndromes. ARF, acute rheumatic fever; RHD, rheumatic heart disease.

Local infection of the oropharynx (pharyngitis) or skin (pyoderma) is mostly benign with spontaneous resolution usually within days. Invasion of Group A *Streptococcus* into normally sterile sites occurs less commonly, but is often severe with clinical manifestations arising from complex host--pathogen interactions. Preceding viral infection, in particular with varicella or influenza A, has been implicated as a frequent antecedent to invasive infection. The skin and throat are the major portals for entry, after which Group A *Streptococcus* evades host defenses by elaborating a number of virulence factors, chief of which is M protein that extends as hair-like filaments from the cell surface. M protein (together with the hyaluronic acid capsule and other surface proteins) enables Group A *Streptococcus* to evade phagocytosis by multiple mechanisms, including preventing opsonization by blocking complement fixation to the bacterial cell wall.

A number of additional cellular products appear to facilitate direct spread of the invading organism through tissue planes and bacteremia can result in hematogenous dissemination. Some strains have the capacity to elaborate pyrogenic exotoxins that may act as "superantigens", leading to polyclonal proliferation of subsets of T lymphocytes, massive cytokine production and shock [@bib7].

Antibodies against Group A *Streptococcus* proteins (in particular antibodies against serotype-specific epitopes on the M protein) are important in providing protection against subsequent infection. However, aberrant immune responses to otherwise benign Group A *Streptococcus* pharyngitis or impetigo can result in the immune-mediated manifestations, acute rheumatic fever and acute post-streptococcal glomerulonephritis. In acute rheumatic fever, cross-reactive antibodies are thought to arise in genetically predisposed individuals infected with rheumatogenic Group A *Streptococcus* strains. These strains elicit immune responses to antigens with a similarity between epitopes on the M protein and certain host proteins contained within endocardial, synovium and neural tissues.

Clinical Features {#s0025}
=================

Group A *Streptococcus* pharyngitis may be mild or associated with high fever, tender anterior cervical lymphadenopathy, tonsillar exudates and raised peripheral white cell count. Symptoms usually resolve after 3--5 days, although suppurative complications (which are now uncommon in industrialized settings) include peritonsillar and retropharyngeal abscess, suppurative lymphadenitis, otitis media, mastoiditis and meningitis. Non-suppurative complications include scarlet fever, acute rheumatic fever or acute post-streptococcal glomerulonephritis. Scarlet fever is characterized by a diffuse blanching rash that spreads from the chest to the abdomen and extremities leaving a sandpaper-like texture to the skin. Desquamation of the fingers, toes, groin and axilla occurs one or more weeks later. The tongue is frequently coated in a white film (white strawberry tongue) that eventually gives way to a beefy red appearance (red strawberry tongue). While most cases are benign, scarlet fever was often lethal in the pre-antibiotic era. Many cases likely represented what would be regarded today as streptococcal toxic shock syndrome (STSS).

In simple impetigo, infection is confined to the epidermis with the formation of superficial crusted lesions on the face or other exposed body parts. In tropical and impoverished settings "pyodermatous" lesions may be pustular and ulcerative. Children are usually afebrile and otherwise well, although resolution of pyoderma may take many days and result in scarring. Erysipelas, which typically affects the face or an extremity, is a painful infection of the dermis resulting in a clearly demarcated red and raised area of inflammation and often formation of superficial bullae. Cellulitis involves the deeper subcutaneous tissues causing a more diffuse and less clearly demarcated area of inflammation. Infection of the draining lymphatic tracts (lymphangitis) results in tender linear streaks extending from the site of infection. Unlike impetigo, cellulitis and erysipelas are usually associated with fever and systemic toxicity.

Necrotizing fasciitis is a rapidly progressing infection of the subcutaneous fat, the superficial fascia and deeper structures, including muscle. Shock, multi-organ failure and death may ensue within hours or days of onset. Initially, the overlying skin is relatively spared and severe escalating pain may be disproportionate to clinical findings. The skin subsequently becomes violaceous and bullae may form and then slough. STSS is characteristically associated with Group A *Streptococcus* necrotizing fasciitis, although it may arise in the setting of other invasive Group A *Streptococcus* infections. The case definition of STSS requires the confirmation of Group A *Streptococcus* infection, along with hypotension and two or more features of multi-organ involvement: rash, coagulopathy, respiratory distress syndrome, renal failure or hepatic impairment [@bib8].

Otitis media, retropharyngeal and peritonsillar abscess, sinusitis, meningitis, pneumonia, bacteremia and endocarditis may arise either as a complication of tonsillopharyngitis, following surgery or trauma (including burns), following varicella infection, or without apparent antecedent. Historically, outbreaks of Group A *Streptococcus* pneumonia were reported among previously healthy adults, although more recent reports have described the highest risk amongst the elderly and those with underlying medical conditions; infection in these individuals is often associated with high case fatality [@bib9]. A viral prodrome is often reported, although the onset of fever, chest pain and dyspnea is characteristically rapid. Group A *Streptococcus* pneumonia may be necrotizing with pleural effusions frequently present early and early complications include lung abscess formation, mediastinitis and pericarditis. Group A *Streptococcus* is an uncommon cause of meningitis in children and adults, with most reports arising in individuals with a pre-existing focus of Group A *Streptococcus* infection (e.g. pharyngitis, otitis media) or with other risk factors (e.g. skull defect or post-cranial surgery) [@bib10]. Puerperal sepsis caused by Group A *Streptococcus* was a frequent cause of death in the pre-antibiotic era with outbreaks resulting from nosocomial transmission. A study in four tropical developing countries (Papua New Guinea, Ethiopia, The Gambia and The Philippines) during the 1990s found that Group A *Streptococcus* was one of the three leading causes of bacteremia in children aged \<90 days, suggesting that Group A *Streptococcus* puerperal sepsis and septic abortion remain common in less developed, tropical countries [@bib11]. Unlike Group B *Streptococcus*, Group A *Streptococcus* more commonly affects the mother than the infant, manifesting as post-partum endometritis, peritonitis, septic thrombophlebitis or bacteremia without focus [@bib12]. However, chorioamnionitis and neonatal sepsis are also reported.

Acute rheumatic fever is characterized by various combinations of fever, polyarthritis or arthralgias, carditis, characteristic rash (erythema marginatum), chorea and subcutaneous nodules [@bib13] ([Table 36-3](#t0020){ref-type="table"}). Chorea and insidious carditis can occur as a manifestation of acute rheumatic fever in the absence of other features. Severe or recurrent episodes of acute rheumatic fever may result in progressive damage to the mitral valve (and sometimes the aortic valve) resulting in incompetence and progressive heart failure (rheumatic heart disease). Over several years, the valve may eventually become stenotic. Acute post-streptococcal glomerulonephritis can occur 1--2 weeks after throat infection or a few weeks after Group A *Streptococcus* skin infection. The features are hematuria (microscopic or gross), edema (which may be most evident peri-orbitally) and hypertension. Severe cases can also be complicated by encephalopathy. The illness is generally benign in childhood, but there may be an appreciable mortality among adults as a result of renal and congestive cardiac failure. Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) is a term used to describe some children with tic or obsessive compulsive disorders in whom symptoms appear to develop or worsen following Group A *Streptococcus* infection. The existence of PANDAS is controversial [@bib14]. Post-streptococcal reactive arthritis describes a syndrome of polyarthritis that differs from acute rheumatic fever by affecting a range of smaller joints, being relatively resistant to anti-inflammatory treatment and not being associated with carditis, although cases of acute rheumatic fever have been mis-diagnosed as post-streptococcal reactive arthritis [@bib15], [@bib16].

Patient Evaluation, Diagnosis and Differential Diagnosis {#s0030}
========================================================

Viruses account for most episodes of acute pharyngitis in all age groups. Group A *Streptococcus* is isolated in only 20--40% of cases of exudative pharyngitis in school-aged children and an even lower proportion of cases in younger children and adults. Recovery of the organism may not represent infection, but colonization. The distinguishing features of Group A *Streptococcus* pharyngitis and scarlet fever, and differential diagnoses, are detailed in [Table 36-2](#t0015){ref-type="table"} .TABLE 36-2Differential Diagnosis for Selected Group A *Streptococcus* Infections and Group A *Streptococcus*-Related Syndromes**Group A *Streptococcus* pharyngitis**PrimaryRhinovirusesCoronavirusesAdenovirusesEpstein-Barr virus (EBV)Enteroviruses•Coryza, rhinorrhea and hoarseness are prominent features of rhinovirus and coronavirus-associated pharyngitis, which is usually non-exudative•Adenovirus may be exudative and associated with conjunctivitis, i.e. "pharyngoconjunctival fever"•EBV-associated pharyngitis is often part of "infectious mononucleosis" and is associated with prominent lymphadenopathy and systemic features, e.g. myalgias and atypical lymphocytosis +/− elevated transaminases•CMV and HIV may both cause a "mononucleosis-like" illness•HIV seroconversion illness may occur in the window period before ELISA tests become positive•Enterovirus "herpangina" is associated with discrete ulcerative lesions of the posterior pharynx•Group C and G streptococci are not thought to cause acute rheumatic fever or acute post-streptococcal glomerulonephritis•*Arcanobacterium haemolyticus* is more common in adolescence and associated with a pleomorphic rash affecting the extensor surfaces and spreading to the neck and trunk•*Neisseria gonorrhoeae* throat infection is more frequently asymptomatic, but should be considered in sexually active individuals•*Mycoplasma pneumoniae* and *C. pneumoniae* produce pharyngitis accompanied by lower respiratory symptoms•Diphtheria is marked by extreme toxicity and the development of a thick pharyngeal exudate. Death is commonly caused by toxin-mediated cardiac suppression or direct invasion of local structures and asphyxiation. Remains a risk in settings where vaccination programmes are poorly established or have been interrupted•Primary HSV gingivostomatitis results in ulcerative lesions of the lips, tongue and buccal mucosa associated with fever, pain and drooling•Acute necrotizing ulcerative gingivitis is caused by infection with mixed anaerobes and oral spirochetes results in painful inflammation and sloughing of the gums. Associated with limited nutrition and dental hygieneSecondaryGroup C and G streptococciCytomegalovirus (CMV)Human immunodeficiency virus (HIV)Other*Arcanobacterium haemolyticusNeisseria gonnorhoeaeMycoplasma pneumoniaeChlamydophila pneumoniaeCorynebacterium diphtheriae*Herpes Simplex Virus (HSV)*Yersinia enterocoliticaFrancisella tularensis*Mixed anaerobes and spirochetes**Scarlet fever**PrimaryMeaslesRubellaRoseolaEBVParvovirus B19•Measles and rubella should be considered, especially if unvaccinated or history of recent contact•Measles is associated with prodromal conjunctivitis and coryzal symptoms and Koplik spots. Rubella is associated with post-auricular lymphadenopathy•Parvovirus "fifth disease or erythema infectiosum" associated with distinctive "slapped cheek" rash of face and reticular rash of limbs appearing after fever resolution•Roseola rash associated with defervescence and affects younger children (infants) more than scarlet fever•Kawasaki disease (KD) and Still\'s disease (SD; systemic-onset juvenile rheumatoid arthritis) associated with multiple symptoms and prolonged fever (\>5 days). KD is also associated with conjunctivitis, edema of the hands and feet, and stomatitis. SD is associated with transient or "evanescent" rash, lymphadenopathy, hepatosplenomegaly, uveitis, +/− arthritisSecondaryKawasaki diseaseStill\'s diseaseEnterovirusesDrug eruptionAnticonvulsant hypersensitivity syndrome**Impetigo**Primary*Staphylococcus aureus*Group C and G beta-hemolytic streptococciScabiesTinea•*Staphylococcus aureus* impetigo is more commonly (but not always) bullous and may co-infect with Group A *Streptococcus* in pyodermatous impetigo•Non-group A beta-hemolytic streptococci may cause clinically indistinguishable lesions to Group A Streptococci, but are not associated with acute rheumatic fever or acute post-streptococcal glomerulonephritis•Scabies may result in crusted lesions and burrows that are itchy and involve the interdigital spaces or diffusely involving the trunk. Infestation may predispose to pyoderma•Tinea causes superficial scaly non-exudative lesions frequently with central sparing**Cellulitis and erysipelas**Primary*S. aureus*Group B, C and G *Streptococcus*•*Staphylococcus aureus* usually associated with clear portal of entry, e.g. wound•Enterobacteriacae, pseudomonas and anaerobes more common in immunocompromised hosts, e.g. diabetic foot infections, neutropenic hosts•HSV associated with vesicular lesions•*Pasteurella multocida*, *E. corredens* and anaerobes following human or animal bites•*Aeromonas* species may be rapidly progressive and associated with water exposure•*Erysipelothrix rhusiopathiae* and contact dermatitis are not associated with toxicity and may be suspected because of distribution (e.g. on hands) and exposure history (e.g. meat-worker)SecondaryEnterobacteriacae*Pseudomonas aeruginosa*HSVAnaerobesOther*Aeromonas* species*Pasteurella multocidaEikenella corredensErysipelothrix rhusiopathiae*Contact dematitis**Necrotizing fasciitis**PrimaryPolymicrobial*Clostridium perfringens*•Unlike other forms of necrotizing fasciitis, Group A *Streptococcus* necrotizing fasciitis is rarely associated with gas formation•Polymicrobial infection may be associated with abdominal surgery or an occult colonic source, typically involving the perineum and abdominal wall (Fournier\'s gangrene) and in patients with diabetes or peripheral vascular disease•Clostridial "gas gangrene": usually secondary to traumatic interruption of vascular supply to affected limb or a colonic pathology in case of *C. septicum*•*Vibrio vulnificus* associated with underlying illnesses and water exposureSecondary*Vibrio vulnificus*Other*Clostridium septicum***Acute rheumatic fever**Primary*S. aureus*Post-streptococcal reactive arthritis (PSRA)•*Staphylococcus aureus* is usually monoarticular. Associated with sepsis and moderate-to-severe toxicity if multifocal. Effusions are purulent and usually (but not always) culture-positive•PSRA associated with small joints and absence of other clinical features of acute rheumatic fever or a propensity to rheumatic heart disease. A diagnosis of PSRA should rarely be made in populations with a high incidence of acute rheumatic fever, and all cases should be given at least 12 months of penicillin prophylaxis before re-evaluation•*Neisseria gonorrhoeae* may be multifocal and migratory, and must be considered if sexually active. Also associated with cutaneous lesions in disseminated disease. Culture of joint fluid is frequently negative•Juvenile rheumatoid arthritis (JRA) arthritis is usually symmetrical, non-migratory and has a more gradual onset. Other features, e.g. iritis and serositis, may be present•Transient synovitis more frequent occurs in younger children, affects the hips, is self- resolving and less associated with raised inflammatory markers and fever•SLE associated with raised antinuclear antibodies and dsDNA•Reactive arthritis is associated with rash of palms and soles, conjunctivitis and urethritisSecondary*N. gonorrhoeae*Rheumatoid arthritisTransient synovitisOtherSystemic lupus erythematosus (SLE)Reactive arthritis**Acute post-streptococcal glomerulonephritis**PrimarySLEIgA nephropathyMesangiocapillary glomerulonephritis (MCGN)Rapidly progressive glomerulonephritis•Post-streptococcal glomerulonephritis distinguished by complement profile (low C3, normal C4) and raised streptococcal serology titers, although these may be coincidentally raised in non-post-streptococcal glomerulonephritis. Also anti-streptolysin O titer (ANA) may be normal if post-streptococcal glomerulonephritis secondary to impetigo•SLE, MCGN and glomerulonephritis of chronic disease are also associated with low C3 which resolves only slowly if untreated (8 weeks or more)•SLE is associated with depressed C4 and other manifestations, e.g. arthritis and/or iritis, positive antinuclear antibodies (ANA) and double-stranded DNA (dsDNA) autoantibodies•MCGN more frequently associated with heavy proteinuria and nephrotic syndrome•Glomerulonephritis of chronic disease is associated with endocarditis, chronic hepatitis B or C, syphilis and malaria. Distinguished from post-streptococcal glomerulonephritis by other features, e.g. fever, positive blood cultures, hepatitis, etc.•Rapidly progressive glomerulonephritis is associated with progression to end-stage renal failure. Occasionally secondary to post-streptococcal glomerulonephritis but may be secondary to SLE (ANA positive) or Wegeners granulomatosis (antineutrophil cytoplasmic antibody (ANCA) positive)SecondaryBenign familial hematuriaHenoch-Schonlein purpuraSickle cell nephropathySubacute endocarditisOtherHemolytic-uremic syndromeTraumaCongenital anomaliesTumor

*Staphylococcus aureus* is a major cause of community-acquired pyogenic infection and an important differential diagnosis for invasive Group A *Streptococcus* infection, especially for skin and osteoarticular infections and necrotizing pneumonia. The features which may help to distinguish Group A *Streptococcus* from *S. aureus* and other skin infections are listed in [Table 36-2](#t0015){ref-type="table"}. In addition, a form of toxic shock syndrome (TSS) may complicate *S. aureus* infection, and shares many features with STSS with the exception that it is more frequently associated with colonization rather than bacteremia or severe underlying infection.

Invasive infections resulting from trauma or bites, exposure to water or soil, or involving immunocompromised hosts (including diabetic foot infections) may be caused by a more expanded array of pathogens and therefore require broader empirical therapy and heightened efforts to obtain a microbiologic diagnosis [@bib17].

The arthritis of acute rheumatic fever may be mistaken for septic arthritis (e.g. the polyarthritis of disseminated gonococcosis or multifocal *S. aureus* infection), rheumatologic causes of polyarthritis, including juvenile rheumatoid arthritis, and post-streptococcal reactive arthritis (see [Table 36-2](#t0015){ref-type="table"}). Acute rheumatic fever is the most common cause of chorea in most populations with a high incidence of acute rheumatic fever---particularly those in tropical, less-developed countries---and can occur in the absence of other features of acute rheumatic fever or serologic evidence of Group A *Streptococcus* infection. However, chorea may also be a manifestation of systemic lupus erythematosus, neurovascular disease, drugs, thyrotoxicosis, Wilson\'s disease and a number of genetic neurodegenerative diseases that must be considered, especially where acute rheumatic fever is uncommon.

Group A *Streptococcus* pharyngitis may be diagnosed presumptively by culturing colonies of Gram-positive cocci displaying surrounding zones of beta-hemolysis on blood agar. Other beta-hemolytic streptococci may colonize the oropharynx (e.g. Group C and G streptococci), and differentiation requires the demonstration of growth inhibition by bacitracin or the use of commercially available, group-specific antigen detection kits. Rapid diagnostic tests have been developed to allow clinicians to reliably distinguish Group A *Streptococcus* from viral pharyngitis at the point of care. Evaluations of these tests suggested variable sensitivity of earlier generation kits (\~85%), but improved sensitivity of later-generation optical immunoassay-based kits and good specificity.

Group A *Streptococcus* cellulitis and erysipelas are clinical diagnoses that are only occasionally confirmed by positive blood cultures. Culture of percutaneous aspirates is helpful if positive, but is usually negative. The clinical suspicion of necrotizing fasciitis or myonecrosis must be confirmed promptly by the demonstration of nonviable tissue at surgery. Imaging results are frequently nondefinitive and may inadvertently delay the diagnosis and institution of appropriate treatment. Group A *Streptococcus* can usually be cultured from operative specimens, if not from blood in patients with necrotizing fasciitis.

The diagnosis of a primary episode of acute rheumatic fever is based on the most recent version of the Jones' criteria---currently the 1992 version ([Table 36-3](#t0020){ref-type="table"} ). These clinical and investigational criteria have been repeatedly revised since the original 1944 version to maintain their positive predictive value in settings where incidence is decreasing. As a result, some high-burden settings have chosen to modify the revised criteria to retain their sensitivity and negative predictive value [@bib18].TABLE 36-3World Health Organization 2002--2003 Criteria for the Diagnosis of Rheumatic Fever and Rheumatic Heart Disease**The Jones Criteria (1992 update):**Major manifestationsCarditis\
Polyarthritis\
Chorea\
Erythema marginatum\
Subcutaneous nodulesMinor manifestationsClinical:Arthralgia\
FeverLaboratory:Elevated acute phase reactants (ESR, leukocyte count)ECG:Prolonged PR intervalEvidence of antecedent Group A *Streptococcus* infectionElevated or rising streptococcal antibody titers (anti-streptrolysin O or anti-DNase B titer)\
Positive throat culture or rapid streptococcal antigen test\
Recent scarlet fever**Diagnostic categories:**Primary episode of acute rheumatic feverTwo major manifestations, or\
one major and two minor manifestations\
plus evidence of antecedent Group A *Streptococcus* infectionRecurrent attack of acute rheumatic fever in a patient with established rheumatic heart diseaseTwo minor manifestations\
plus evidence of antecedent Group A *Streptococcus* infectionRecurrent attack of acute rheumatic fever in a patient with established rheumatic heart diseaseTwo major manifestations, or\
one major and two minor manifestations\
plus evidence of antecedent Group A *Streptococcus* infectionRheumatic chorea\
Insidious onset rheumatic carditisOther major manifestations or evidence of Group A streptococcal infection not requiredChronic valve lesions of rheumatic heart disease (patients presenting for the first time with pure mitral stenosis or mixed mitral valve disease and/or aortic valve disease)Do not require any other criteria to be presenting for the first time with pure diagnosed as having rheumatic heart diseaseReproduced with permission from World Health Organization. Rheumatic Fever and Rheumatic Heart Disease: Report of a WHO Expert Consultation. Report No. 923. Geneva: World Health Organization; 2004.

In acute post-streptococcal glomerulonephritis, activation of the alternative complement pathway results in a depressed C3 level (usually with a normal C4) that resolves after several weeks. Diagnosis generally rests on the presence of signs and symptoms, together with serologic evidence of recent Group A *Streptococcus* infection and a compatible complement profile. Biopsy is reserved for atypical features, such as anuria or failure of renal function, hypertension or depressed complement that does not improve after several weeks.

Treatment {#s0035}
=========

Penicillin remains the antibiotic of choice for most Group A *Streptococcus* infections. Group A *Streptococcus* remains universally sensitive to penicillin and, while treatment failures occur, they invariably relate to lack of *in vivo* efficacy rather than *in vitro* non-susceptibility. As penicillins target cell wall synthesis, they may be less effective in the stationary phase of bacterial growth as they may occur in severe infections complicated by large bacterial loads [@bib19]. However, even in instances where alternative antibiotics may be preferred because of differing mechanisms of action, they are generally used as an adjunct to---rather than in replacement of---penicillin therapy. Erythromycin and the newer macrolides have been used for Group A *Streptococcus* disease where individuals have immediate hypersensitivity to penicillin. Macrolide resistance is common in some settings and can arise abruptly, apparently related to the population level of macrolide consumption. Some mutations confer resistance to both macrolides and clindamycin, but these remain uncommon.

The use of antibiotics for the routine treatment of Group A *Streptococcus* pharyngitis is contentious because of the usually self-limiting nature of the illness. Studies suggest that treatment reduces the average duration of sore throat by 16 hours and decreases the risk of rheumatic fever and otitis media by around 70%, and the risk of peritonsillar abscess by around 85% [@bib20]. In low-incidence settings, the numbers needed to treat to prevent complications is likely to be very large, so the main aim of antibiotic treatment, if chosen to be used, is alleviation of symptoms and shortening of the duration of illness. However, antibiotic treatment of Group A *Streptococcus* pharyngitis is essential in populations with a high incidence of acute rheumatic fever and, if diagnostic facilities are limited, empirical treatment of all sore throat cases may be justified. There is little evidence that antibiotics reduce the risk of subsequent acute post-streptococcal glomerulonephritis.

Treatment recommendations are detailed in [Table 36-4](#t0025){ref-type="table"} . Ten days of twice-daily oral penicillin V or a single dose of intramuscular benzathine pencillin G are the preferred treatment for Group A *Streptococcus* pharyngitis, although once-daily oral amoxicillin appears to be effective for symptom resolution and Group A *Streptococcus* eradication [@bib21]. Short courses (up to 5 days) of macrolides and some cephalosporins have been shown to have equivalent clinical and short-term microbiologic cure rates, but the risk of late microbiologic failure may be higher. There are insufficient data regarding the efficacy of short-course or non-penicillin regimens in preventing acute rheumatic fever. Treatment of impetigo may be with oral or topical antibiotics---options are given in [Table 36-4](#t0025){ref-type="table"}.TABLE 36-4Antibiotic Treatment Guidelines for Selected Group A *Streptococcus* InfectionsRationaleMedicationEvidence[\*](#tn0025){ref-type="table-fn"}DoseCommentsGroup A Streptococcus pharyngitis•Prevention of acute rheumatic fever in moderate-to-high endemic settings•Prevention of suppurative complications•Alleviation of symptoms•Prevent secondary casesOral phenoxymethylpenicillin (penicillin V)110 mg/kg up to 500 mg BD for 10 daysTreatment may be primarily for symptom alleviation unless the risk of sequelae is highOral amoxicillin1≤30 kg: 750 mg daily for 10 days\
\>30 kg: 1500 mg daily for 10 daysNot proven to prevent acute rheumatic feverIM benzathine penicillin G13--6kg: 225 mg\
6--10kg: 337.5 mg\
10--15kg: 450 mg\
15--20kg: 675 mg\
20+ kg: 900 mg as a single dosePreferred where risk of rheumatic fever is high and adherence to oral therapy not assuredOral roxithromycin[†](#tn0030){ref-type="table-fn"}120 mg/kg up to 500 mg daily for 3 daysIf hypersensitive to penicillinImpetigo•Alleviate symptoms•Prevent secondary cases•Possibly prevent invasive complicationsTopical mupirocin 2% ointment18-hourly for 7 daysPreferred for mild disease, but not proven in high-endemic settings. Use saline, soap water or 0.1% potassium permanganate to remove crusts prior to applying. Strains of *Staphylococcus aureus* may be resistant or may acquire resistance to topical antibioticsOral di/flucloxacillin112.5 mg/kg up to 500 mg q 6-hourly for 10 daysFirst-line treatment if multiple lesions and *S. aureus* is likelyIM benzathine penicillin G13--6kg: 225 mg\
6--10kg: 337.5 mg\
10--15kg: 450 mg\
15--20kg: 675 mg\
20+ kg: 900 mg as a single dosePreferred in endemic settings where risk of acute post-streptococcal glomerulonephritis is high and/or adherence to oral therapy not assured. Exclude *S. aureus* infection if refractory to treatmentOral erythromycin112.5 mg/kg up to 500 mg TDS for 10 daysIf hypersensitive to penicillinErysipelas and cellulitis mild/early•Alleviate symptoms•Prevent progression•Prevent complicationsOral di/flucloxacillin112.5 mg/kg up to 500 mg q 6-hourly for 7--10 daysSwitch to IV therapy if failure to respond and consider resistant pathogens, e.g. methicillin-resistant *Staphylococcus aureus* (MRSA)Oral phenoxymethylpenicillin\
(penicillin V)210 mg/kg up to 500 mg BD for 10 daysIf *S. aureus* is unlikely (e.g. early erysipelas or perianal cellulitis) or if Group A *Streptococcus* confirmed on culture. Exclude *S. aureus* infection if refractory to treatmentOral cephalexin112.5 mg/kg up to 500 mg q 8hourly for 7--10 daysIf non-immediate type hypersensitivity to penicillinsOral clindamycin110 mg/kg up to 450 mg q 8-hourly for 7--10daysIf immediate type hypersensitivity to penicillin or infection with clindamycin-sensitive MRSA likelyErysipelas and cellulitis moderate-to-severe•Alleviate symptoms•Prevent complicationsIV di/flucloxacillin150 mg/kg up to 2 g q 6-hourlyPreferred treatment unless MRSA is likelyIV cephalothin250 mg/kg up to 2 g q 6-hourlyIf non-immediate type hypersensitivity to penicillinIV/Oral clindamycin110 mg/kg up to 450 mg q 8-hourly for 7--10 daysIf immediate type hypersensitivity to penicillin or infection with clindamycin sensitive MRSA likely. Bioavailability of clindamycin is high so oral clindamycin can be considered except in infantsIV vancomycin125 mg/kg (\<12 yr use 30 mg/kg) up to 1g BDIf infection with clindamycin-resistant MRSA likely. Adjust dose on basis of trough blood levelsNecrotizing fasciitis[§](#tn0035){ref-type="table-fn"}Prevent deathPrevent complicationsAlleviate symptomsMinimize disfigurementIV meropenem525 mg/kg up to 1 g q 8-hourlyBroad-spectrum cover is recommended in addition to surgical debridement until Group A *Streptococcus* infection is confirmed, thereafter penicillin + clindamycin is recommendedIV benzylpenicillin245 mg/kg up to 1.8 g q 4-hourlyIf Group A *Streptococcus* infection is confirmed. Use in addition to surgical debridementIV cephalothin550 mg/kg up to 2 g q 6-hourlyIf GAS confirmed and non-immediate type hypersensitivity to penicillin. If there is a history of immediate-type hypersensitivity to ß-lactams, seek expert advice+ IV clindamycin215 mg/kg up to 600 mg q 8-hourlyUse as an adjunct to meropenem or penicillin if Group A *Streptococcus* infection is suspected or confirmedStreptococcal toxic shock syndrome (STSS)[§](#tn0035){ref-type="table-fn"}•Prevent death•Minimize complicationsIntravenous immunoglobulin (IVIG)42 g/kg as an immediate infusion, repeated once in 48--72 h if necessaryUse as an adjunct to penicillin and clindamycin therapy +/− debridement as recommended above for necrotizing fasciitisAcute rheumatic fever treatment•Alleviate symptoms•Prevent death from acute cardiac failureAspirin180--100mg/kg/day (up to 4--8 g/day) in 4--5 divided dosesFor the control of pain of acute rheumatic fever arthritis. Duration dependent on clinical responseIM benzathine penicillin G5≤20 kg: 450 mg as a single dose\
\>20 kg: 900 mg as a single dosePreferred where adherence to oral therapy not assured. Treatment should focus on pain relief with salicylates and management of cardiac failureOral phenoxymethylpenicillin (penicillin V)5250 mg BD for 10 daysAn acceptable alternative to benzathine penicillin if adherence can be assured, e.g. in hospitalOral prednisolone51--2 mg/kg/day (up to 80 mg/day)Not routinely recommended for carditis, but may be considered for severe carditis if surgery is not an optionCarbamazepine37--10 mg/kg/day in 3 divided dosesNot routinely recommended for management of chorea, but may be considered in severe casesAcute rheumatic fever prophylaxis•Prevent further episodes of acute rheumatid fever•Prevent progressive carditisIM benzathine penicillin G1\<20 kg: 450 mg\
\>20 kg: 900 mg every 3--4 weeksPreferred regimen. Should be continued for at least 10 years and at least until patient is 21 years old. Patients with established valve disease may require longer duration. Four-weekly injections satisfactory if a good control programme is in placeOral phenoxymethylpenicillin (penicillin V)1250 mg BDAssociated with inferior adherence. Only where IM injections are refused or risk of progressive carditis very lowOral erythromycin5250 mg BDIf hypersensitive to penicillin. Dose for erythromycin ethyl succinate is 400 mg BD[^5][^6][^7]

Penicillin is the treatment of choice for invasive infection where Group A *Streptococcus* is confirmed or highly likely (e.g. erysipelas or perianal cellulitis). Because of the narrow spectrum of penicillin, empirical treatment prior to microbiologic confirmation is generally with one or more alternative antimicrobials. For example, an anti-staphylococcal penicillin or a first-generation cephalosporin is required to cover both Group A *Streptococcus* and *S. aureus* in cellulitis (see [Table 36-4](#t0025){ref-type="table"}). Where methicillin-resistant *S. aureus* (MRSA) is prevalent, clindamycin may be an acceptable alternative if prevailing MRSA strains are susceptible. Suppurative diseases frequently seen as complications of Group A *Streptococcus* infection (e.g. peritonsillar abscess) may also be caused by organisms other than Group A *Streptococcus*.

As necrotizing soft tissue infections may be polymicrobial, broad-spectrum cover (e.g. with a carbapenem) is recommended until the microbiologic cause is confirmed.

Urgent and aggressive debridement of nonviable tissues has been the cornerstone of management of Group A *Streptococcus* necrotizing fasciitis, along with intensive supportive care and antibiotics. However, some authorities have suggested that a less aggressive approach may be acceptable if antibiotics and adjunctive therapy with intravenous immunoglobulin (IVIG) are instituted early [@bib22]. Clindamycin is recommended as an adjunct to penicillin for the treatment of severe invasive Group A *Streptococcus* disease, including necrotizing infections, during the first few days of treatment---this is supported by the superior activity of clindamycin over penicillin in animal models [@bib19]. However, penicillin should always be given unless there is a history of hypersensitivity. Although supportive data are limited, administration of 1 or 2 doses of IVIG early in the course of STSS is widely recommended. A multicenter, randomized, controlled trial revealed a trend toward a reduction in mortality among recipients, but the study was terminated early because of slow recruitment [@bib23]. IVIG is also recommended by some as adjunctive treatment in severe invasive Group A *Streptococcus* infections, even in the absence of toxic shock.

Management of acute rheumatic fever is primarily symptomatic. Penicillin is generally given to eradicate colonization, although acute infection has usually passed by the time symptoms of acute rheumatic fever develop. Salicylates are used to relieve fever and the pain from arthritis that is often severe. Where necessary, cardiac failure is managed with diuretics and angiotensin-converting enzyme (ACE) inhibitors. Steroids are sometimes used in cases of severe carditis, although there is no evidence that they improve the long-term outcome in RHD. Mitral valve repair, balloon valvuloplasty, or valve replacement may be required to manage patients with severe valve disease in rheumatic heart disease.

Management of acute post-streptococcal glomerulonephritis is based on control of hypertension with fluid restriction and use of a loop diuretic such as furosemide. ACE inhibitors may also be needed as an adjunct. Dialysis is occasionally required to manage severe hyperkalemia or symptomatic uremia.

Contacts of patients with Group A *Streptococcus* infection may be colonized with the same Group A *Streptococcus* strain, but primary prophylaxis of contacts is rarely indicated for simple Group A *Streptococcus* pharyngitis. Even for contacts of severe invasive infections, it is estimated that around 2000 contacts would need to receive prophylaxis in order to avoid a single, severe infection---opinion on the value of treating contacts is divided [@bib24]. If prophylactic treatment of contacts is attempted, regimens combining rifampin with penicillin, or using alternative antibiotics such as cephalosporins or azithromycin, are usually recommended as a result of the increasing failures of penicillin alone in eradicating carriage.

However, regular secondary prophylaxis *is* recommended for all children and adults with previous acute rheumatic fever or established rheumatic heart disease. Monthly intramuscular benzathine penicillin G is central to the management of children and adults with acute rheumatic fever and rheumatic heart disease (see [Table 36-4](#t0025){ref-type="table"}).

During outbreaks of acute post-streptococcal glomerulonephritis secondary to Group A *Streptococcus* pyoderma, community-based treatment of infected individuals and their contacts with benzathine penicillin G appears to decrease the transmission of acute post-streptococcal glomerulonephritis-producing Group A *Streptococcus* strains. In addition to treating infected individuals, reducing the transmission of Group A *Streptococcus* pyoderma in resource-limited settings is likely to require skin hygiene measures, including the control of scabies.

After a century of research, the development of a vaccine against Group A *Streptococcus* disease is at last showing promise. The most advanced of the current candidates is a multivalent vaccine including 26 of the most common Group A *Streptococcus emm* types encountered in North America and Europe. Unfortunately, there is a limited match of these strains with prevalent *emm* types in Africa and the Pacific, where *emm* types are more variable [@bib25]. Other candidate vaccines, containing antigens conserved among most, or all, Group A *Streptococcus* strains, are approaching clinical trials.

[^1]: All estimates rounded-off. Note that these estimates assume constancy of incidence and prevalence over time.

[^2]: New RHD cases were calculated based on the proportion of incident acute rheumatic fever cases expected to develop RHD. The remainder of incident acute rheumatic fever cases are included in the "History of acute rheumatic fever without carditis" row. Therefore, the total number of new acute rheumatic fever cases each year is 282,000 + 188,000 = 470,000.

[^3]: Includes acute rheumatic fever deaths. RHD deaths are based on proportion of existing RHD cases expected to die each year.

[^4]: No attempt has been made to quantify the prevalence of acute post-streptococcal glomerulonephritis-induced chronic renal impairment or end-stage renal failure.

[^5]: Level of evidence: 1=randomized controlled trial, 2=comparative clinical study \> 20 patients, 3=comparative clinical study \< 20 patients, 4=case series, 5=expert opinion on basis of *in vitro* data or animal studies.

[^6]: Roxithromycin, semi-synthetic macrolide not commercially available in the USA.

[^7]: Intravenous immune globulin (IVIG) 2 g/kg as a single infusion, repeated if necessary 24--48 hours later is also recommended for necrotizing fasciitis or other severe invasive Group A *Streptococcus* infections (e.g. impending STSS). If indicated, IVIG should be administered as early as possible.
